Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Clinical Pharmacology Education - The Decade Ahead.

Brouwer KLR, Schmidt S, Floren LC, Johnson JA.

Clin Pharmacol Ther. 2019 Nov 10. doi: 10.1002/cpt.1652. [Epub ahead of print] No abstract available.

PMID:
31709518
2.

Can they imagine the future? A qualitative study exploring the skills employers seek in pharmaceutical sciences doctoral graduates.

McLaughlin JE, Minshew LM, Gonzalez D, Lamb K, Klus NJ, Aubé J, Cox W, Brouwer KLR.

PLoS One. 2019 Sep 9;14(9):e0222422. doi: 10.1371/journal.pone.0222422. eCollection 2019.

3.

Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Kang HE, Malinen MM, Saran C, Honkakoski P, Brouwer KLR.

Drug Metab Dispos. 2019 Oct;47(10):1222-1230. doi: 10.1124/dmd.119.087676. Epub 2019 Aug 1.

PMID:
31371422
4.

Novel Mechanisms of Valproate Hepatotoxicity: Impaired Mrp2 Trafficking and Hepatocyte Depolarization.

Fu D, Cardona P, Ho H, Watkins PB, Brouwer KLR.

Toxicol Sci. 2019 Jul 31. pii: kfz154. doi: 10.1093/toxsci/kfz154. [Epub ahead of print]

PMID:
31368504
5.

Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.

Ali I, Guidone D, Nicolazzo JA, Brouwer KLR.

Br J Clin Pharmacol. 2019 Oct;85(10):2351-2359. doi: 10.1111/bcp.14049. Epub 2019 Aug 19.

PMID:
31269278
6.

Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Bezençon J, Beaudoin JJ, Ito K, Fu D, Roth SE, Brock WJ, Brouwer KLR.

Drug Metab Dispos. 2019 Aug;47(8):899-906. doi: 10.1124/dmd.119.086785. Epub 2019 Jun 3.

PMID:
31160314
7.

Cefazolin pharmacokinetics in premature infants.

Balevic SJ, Smith PB, Testoni D, Wu H, Brouwer KLR, Zimmerman KO, Rivera-Chaparro ND, Benjamin DK Jr, Cohen-Wolkowiez M.

J Perinatol. 2019 Sep;39(9):1213-1218. doi: 10.1038/s41372-019-0368-z. Epub 2019 Apr 3.

8.

Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease.

Pan Y, Omori K, Ali I, Tachikawa M, Terasaki T, Brouwer KLR, Nicolazzo JA.

J Pharm Sci. 2019 Jul;108(7):2484-2489. doi: 10.1016/j.xphs.2019.02.016. Epub 2019 Feb 27.

PMID:
30825461
9.

Protein expression and function of organic anion transporters in short-term and long-term cultures of Huh7 human hepatoma cells.

Malinen MM, Ito K, Kang HE, Honkakoski P, Brouwer KLR.

Eur J Pharm Sci. 2019 Mar 15;130:186-195. doi: 10.1016/j.ejps.2019.01.022. Epub 2019 Jan 24.

PMID:
30685239
10.

Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

Ali I, Khalid S, Stieger B, Brouwer KLR.

Mol Pharm. 2019 Mar 4;16(3):1406-1411. doi: 10.1021/acs.molpharmaceut.8b01124. Epub 2019 Jan 25.

PMID:
30608704
11.

Continuum of Host-Gut Microbial Co-metabolism: Host CYP3A4/3A7 are Responsible for Tertiary Oxidations of Deoxycholate Species.

Zhang J, Gao LZ, Chen YJ, Zhu PP, Yin SS, Su MM, Ni Y, Miao J, Wu WL, Chen H, Brouwer KLR, Liu CX, Xu L, Jia W, Lan K.

Drug Metab Dispos. 2019 Mar;47(3):283-294. doi: 10.1124/dmd.118.085670. Epub 2019 Jan 3.

PMID:
30606729
12.

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.

Beaudoin JJ, Bezençon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR.

Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):328.

PMID:
30504136
13.

Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Malinen MM, Kauttonen A, Beaudoin JJ, Sjöstedt N, Honkakoski P, Brouwer KLR.

Mol Pharm. 2019 Jan 7;16(1):238-246. doi: 10.1021/acs.molpharmaceut.8b00966. Epub 2018 Dec 14.

PMID:
30481467
14.

A Challenge for Clinical Pharmacologists: How Can We Measure Scientific Impact of Publications in Drug Development and in Regulatory Decision Making?

Schmith VD, Reynolds KS, Brouwer KLR, Vicini P.

Clin Pharmacol Ther. 2019 May;105(5):1071-1073. doi: 10.1002/cpt.1236. Epub 2018 Nov 11. No abstract available.

PMID:
30417325
15.

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.

Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):916-932. doi: 10.1002/cpt.1222. Review.

16.

Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Pan Y, Omori K, Ali I, Tachikawa M, Terasaki T, Brouwer KLR, Nicolazzo JA.

Mol Pharm. 2018 Sep 4;15(9):4073-4083. doi: 10.1021/acs.molpharmaceut.8b00500. Epub 2018 Aug 22.

17.

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):865-889. doi: 10.1002/cpt.1183. Epub 2018 Sep 12.

18.

Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO.

Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):629-637. doi: 10.1002/psp4.12338. Epub 2018 Aug 13.

19.

Analysis of human C24 bile acids metabolome in serum and urine based on enzyme digestion of conjugated bile acids and LC-MS determination of unconjugated bile acids.

Zhu P, Zhang J, Chen Y, Yin S, Su M, Xie G, Brouwer KLR, Liu C, Lan K, Jia W.

Anal Bioanal Chem. 2018 Aug;410(21):5287-5300. doi: 10.1007/s00216-018-1183-7. Epub 2018 Jun 16.

20.

A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.

Karageorgis A, Lenhard SC, Yerby B, Forsgren MF, Liachenko S, Johansson E, Pilling MA, Peterson RA, Yang X, Williams DP, Ungersma SE, Morgan RE, Brouwer KLR, Jucker BM, Hockings PD.

PLoS One. 2018 May 17;13(5):e0197213. doi: 10.1371/journal.pone.0197213. eCollection 2018.

21.

Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):900-915. doi: 10.1002/cpt.1115. Epub 2018 Jul 12.

22.

Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Brock WJ, Beaudoin JJ, Slizgi JR, Su M, Jia W, Roth SE, Brouwer KLR.

Int J Toxicol. 2018 Mar/Apr;37(2):144-154. doi: 10.1177/1091581818760746.

23.

Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers.

Kaullen JD, Owen JS, Brouwer KLR, Heerdt PM, Lien CA, Savarese JJ, Schmith VD.

Anesthesiology. 2018 Jun;128(6):1107-1116. doi: 10.1097/ALN.0000000000002157.

24.

Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.

Guo C, LaCerte C, Edwards JE, Brouwer KR, Brouwer KLR.

J Pharmacol Exp Ther. 2018 May;365(2):413-421. doi: 10.1124/jpet.117.246033. Epub 2018 Feb 27.

25.

Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.

Malinen MM, Ali I, Bezençon J, Beaudoin JJ, Brouwer KLR.

Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609. doi: 10.1152/ajpgi.00310.2017. Epub 2018 Feb 8.

26.

Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

Ali I, Slizgi JR, Kaullen JD, Ivanovic M, Niemi M, Stewart PW, Barritt AS 4th, Brouwer KLR.

Clin Pharmacol Ther. 2017 Dec 22. doi: 10.1002/cpt.997. [Epub ahead of print]

27.

In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer KLR, Casey WM, Choksi N, Ferguson SS, Fraczkiewicz G, Jarabek AM, Ke A, Lumen A, Lynn SG, Paini A, Price PS, Ring C, Simon TW, Sipes NS, Sprankle CS, Strickland J, Troutman J, Wetmore BA, Kleinstreuer NC.

Toxicol In Vitro. 2018 Mar;47:213-227. doi: 10.1016/j.tiv.2017.11.016. Epub 2017 Dec 5. Review.

PMID:
29203341
28.

Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit.

Watt KM, Cohen-Wolkowiez M, Williams DC, Bonadonna DK, Cheifetz IM, Thakker D, Benjamin DK Jr, Brouwer KLR.

J Extra Corpor Technol. 2017 Sep;49(3):150-159.

29.

Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR.

Clin Transl Sci. 2017 Nov;10(6):443-454. doi: 10.1111/cts.12490. Epub 2017 Aug 10. Review. No abstract available.

30.

Effect of Liver Disease on Hepatic Transporter Expression and Function.

Thakkar N, Slizgi JR, Brouwer KLR.

J Pharm Sci. 2017 Sep;106(9):2282-2294. doi: 10.1016/j.xphs.2017.04.053. Epub 2017 Apr 30. Review.

31.

Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors?

Guo C, Yang K, Liao M, Xia CQ, Brouwer KR, Brouwer KLR.

J Pharm Sci. 2017 Sep;106(9):2401-2406. doi: 10.1016/j.xphs.2017.04.054. Epub 2017 Apr 30.

32.

Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay.

Ali I, Welch MA, Lu Y, Swaan PW, Brouwer KLR.

Eur J Pharm Sci. 2017 May 30;103:52-59. doi: 10.1016/j.ejps.2017.02.011. Epub 2017 Feb 24.

33.

Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.

Autmizguine J, Hornik CP, Benjamin DK Jr, Brouwer KL, Hupp SR, Cohen-Wolkowiez M, Watt KM.

Pediatr Infect Dis J. 2016 Nov;35(11):1204-1210.

34.

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, Grammatopoulos TN, Stiles L, Siler SQ, Howell BA, Mosedale M, Watkins PB, Shoda LK.

Toxicol Sci. 2017 Jan;155(1):61-74. doi: 10.1093/toxsci/kfw193. Epub 2016 Sep 21.

35.

Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.

Wells MA, Vendrov KC, Edin ML, Ferslew BC, Zha W, Nguyen BK, Church RJ, Lih FB, DeGraff LM, Brouwer KL, Barritt AS 4th, Zeldin DC, Lee CR.

Prostaglandins Other Lipid Mediat. 2016 Sep;125:19-29. doi: 10.1016/j.prostaglandins.2016.07.002. Epub 2016 Jul 9.

36.

Key Role for the 12-Hydroxy Group in the Negative Ion Fragmentation of Unconjugated C24 Bile Acids.

Lan K, Su M, Xie G, Ferslew BC, Brouwer KL, Rajani C, Liu C, Jia W.

Anal Chem. 2016 Jul 19;88(14):7041-8. doi: 10.1021/acs.analchem.6b00573. Epub 2016 Jun 30.

37.

Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.

Guo C, Yang K, Brouwer KR, St Claire RL 3rd, Brouwer KL.

J Pharmacol Exp Ther. 2016 Aug;358(2):324-33. doi: 10.1124/jpet.116.231928. Epub 2016 May 27.

38.

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes.

Lu Y, Slizgi JR, Brouwer KR, Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL.

Drug Metab Dispos. 2016 Jun;44(6). pii: dmd.115.067629. doi: 10.1124/dmd.115.067629. Epub 2016 Mar 24.

39.

Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Yang K, Guo C, Woodhead JL, St Claire RL 3rd, Watkins PB, Siler SQ, Howell BA, Brouwer KLR.

J Pharm Sci. 2016 Feb;105(2):443-459. doi: 10.1016/j.xphs.2015.11.008. Review.

40.

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL.

Toxicol Sci. 2016 Jan;149(1):237-50. doi: 10.1093/toxsci/kfv231. Epub 2015 Oct 26.

41.

Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.

Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer KL, Barritt AS 4th.

Dig Dis Sci. 2015 Nov;60(11):3318-28. doi: 10.1007/s10620-015-3776-8. Epub 2015 Jul 3.

42.

Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group.

Clin Pharmacol Ther. 2015 Sep;98(3):266-87. doi: 10.1002/cpt.176. Review.

43.

Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.

Watt KM, Gonzalez D, Benjamin DK Jr, Brouwer KL, Wade KC, Capparelli E, Barrett J, Cohen-Wolkowiez M.

Antimicrob Agents Chemother. 2015 Jul;59(7):3935-43. doi: 10.1128/AAC.00102-15. Epub 2015 Apr 20.

44.

Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.

Welch MA, Köck K, Urban TJ, Brouwer KL, Swaan PW.

Drug Metab Dispos. 2015 May;43(5):725-34. doi: 10.1124/dmd.114.062539. Epub 2015 Mar 3.

45.

Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.

Yang K, Pfeifer ND, Köck K, Brouwer KL.

J Pharmacol Exp Ther. 2015 May;353(2):415-23. doi: 10.1124/jpet.114.221564. Epub 2015 Feb 23.

46.

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Ferslew BC, Johnston CK, Tsakalozou E, Bridges AS, Paine MF, Jia W, Stewart PW, Barritt AS 4th, Brouwer KL.

Clin Pharmacol Ther. 2015 Apr;97(4):419-27. doi: 10.1002/cpt.66. Epub 2015 Mar 15.

47.

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.

Woodhead JL, Yang K, Siler SQ, Watkins PB, Brouwer KL, Barton HA, Howell BA.

Front Pharmacol. 2014 Nov 7;5:240. doi: 10.3389/fphar.2014.00240. eCollection 2014.

48.

Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation.

Powell J, Farasyn T, Köck K, Meng X, Pahwa S, Brouwer KL, Yue W.

Drug Metab Dispos. 2014 Nov;42(11):1964-70. doi: 10.1124/dmd.114.056945. Epub 2014 Sep 8.

49.

Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.

Yang K, Woodhead JL, Watkins PB, Howell BA, Brouwer KL.

Clin Pharmacol Ther. 2014 Nov;96(5):589-98. doi: 10.1038/clpt.2014.158. Epub 2014 Jul 28.

50.

Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF.

Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1073-82. doi: 10.1097/MEG.0000000000000152.

Supplemental Content

Loading ...
Support Center